Clinical trial
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in…
NCT00109239 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109239 |
|---|---|
| Title | A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer |
| Official title | A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | rhuMAb VEGF (Bevacizumab) |
| Start date | Nov 1, 2000 |
| Completion | Sep 1, 2002 |
| First posted | Apr 26, 2005 |
| Last update posted | Jun 18, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: